Jonathan L. Silberstein, MD
Department of Urology
Chief of Section Urologic Oncology
Tulane University School of Medicine
1430 Tulane Ave, SL-42
New Orleans, LA 70112, USA
Dr. Silberstein was recruited to join the faculty at Tulane University School of Medicine in 2013 from Memorial Sloan Kettering Cancer Center. He is the Chief of the Section of Urologic Oncology at Tulane and works closely with medical oncologists and radiation oncologists to find the correct individualized treatment for each patient and does not believe in a one size fits all approach. He treats and cares for all patients with localized and advanced urologic malignancies including prostate cancer, bladder cancer, kidney cancer and testis cancer. He is a leader in robotic surgery and has a great deal of experience performing robotic prostatectomies, robotic partial (trans and retroperitoneal) and radical nephrectomies and robotic cystectomies, with and without intracorporeal urinary diversion. Like any other surgical tool, he utilizes the robot when appropriate for the patient and uses open surgery when he believes that will result in a better oncologic outcome.
He was born and raised in New York City and earned his medical degree at SUNY Upstate Medical University in Syracuse, He completed his general surgery internship and his urology residency at the University of California in San Diego. After completing chief residency in San Diego he spent the next three years at Memorial Sloan Kettering Cancer Center, a premiere center in the United States for the management of surgical oncology. At Memorial Sloan Kettering Cancer Center he completed a fellowship and junior faculty position treating patients from around the globe with extremely complex and challenging cancer diagnoses. Following his residency, Dr. Silberstein completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center. He is the author of more than 60 peer-reviewed publications and several book chapters- demonstrating his commitment both to his patients and moving the field forward. He is also the winner of numerous awards from national and international meetings and is a reviewer and editor for several prominent urologic journals.
His research interests include: Urologic Oncology, Advanced Prostate Cancer, Localized Prostate Cancer, Advanced Kidney Cancer, Localized Kidney Cancer, Bladder Cancer, Testicular Cancer, 3D Printing, 3D Modeling, Education, Active Surveillance, Race, Ethnicity, Cancer Bio-Markers, Predictive Markers.
HONORS AND AWARDS
• Deans List: University of Pennsylvania (1999)
• Commendation from the Committee on Academic Promotions, SUNY (2001, 2002)
• Student Investigator Scholarship, American Society of Hematology (2002)
• Alpha Omega Alpha (AOA) (2003)
• UCSD Laurence F. Greene Award for AUA In-service Performance (2008, 2010)
• Western Section AUA: Miley B. Wesson Resident Essay Contest winner (2008)
• Western Section AUA: Best of session Poster; 1st place (2009)
• European Association of Urologists 26th Congress, Vienna, Best of Session (2011)
• AUA 2015, New Orleans: Best Video Abstract- Award Winning Video (2015)
• Alpha Omega Alpha (2003-Present)
• American Urological Association (2005-Present)
• Society of Urologic Oncology (2011-Present)
• American Society of Clinical Oncology (2011-Present)
• American College of Surgeons (2011-Present)
• Society of Laproendoscopic Surgeons (2012-Present)
• Society of Robotic Surgery (2012-Present)
• Endourological Society (2013-Present)
• National Cancer Institute Member #52652 (2013-Present)
• Southwest Oncology Group #51240 (2013-Present)
1. Knoedler M, Feibus A, Lange A, et al. Individualized Physical 3D Kidney Tumor Models Constructed from 3D Printers Result in Improved Trainee Anatomic Understanding. Urology. 2015; 85(6): 1257-1262. doi: 10.1016/j.urology.2015.02.053.
2. Silberstein JL. Individualized Physical 3D Kidney Tumor Models Constructed from 3D Printers Result in Improved Trainee Anatomic Understanding. Urology. 2015; 85(6): 1262.
3. Eggener SE, Badani K, Barocas DA, et al. Gleason 6 Prostate Cancer: Translating Biology into Population Health. J Urol. 2015. doi: 10.1016/j.juro.2015.01.126
4. Silberstein JL. Editorial Comment from Dr. Silberstein to 3-D printing in urological surgery: What are the possibilities? Int J Urol. 2015. doi: 10.1111/iju.12743
5. Bochner BH, Dalbagni G, Sjoberg DD, et al. Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A randomized Clinical Trial. Eur Urol. 2014. doi: 10.1016/j.eururo.2014.11.043
6. Silberstein JL, Eastham JA. Significance and management of positive margins at the time of prostatectomy. J Indian Urology. 2014; 30(4): 423-428. doi: 10.4103/0970-1591.134240
7. Gur S, Sikka SC, Kadowitz PJ, Silberstein J, Hellstrom WJ. 2014 Update of Erectile Dysfunction Management Following Radical Prostatectomy; From Basic Research to Clinical Management. Curr Pharm Des. 2014.
8. Silberstein JL. Outcomes of Retroperitoneal Lymph Node Dissection for the Most Challenging Cases. J Urol. 2014. doi: 10.1016/j.juro.2014.08.058.
9. Bochner BH, Sjoberg DD, Dalbagni G, et al. A randomized trial of robot-assisted laparoscopic radical cystectomy. NEJM. 2014; 371(4): 389-390. doi: 10.1056/NEJMc1405213
10. Silberstein JL, Feibus A, Maddox MM, et al. Active Surveillance of Prostate cancer in African American Men. Urology. 2014; 84(6): 1255-1262. doi: 10.1016/j.urology.2014.06.064
11. Silberstein JL, Maddox MM, Feibus A, Dorsey P, Thomas R, Lee BR. Physical models of renal malignancies using standard cross-sectional imaging and three-dimensional printers: A pilot study. Urology. 2014; 84(2): 268-272. doi: 10.1016/j.urology.2014.03.042
12. Sartor O, Silberstein J. Prostate cancer: Primary ADT monotherapy not suitable for localized disease. Nat Rev Urol. 2014; 11(6): 309-310. doi: 10.1038/nrurol.2014.119
13. Musser JE, Assel M, Guglielmetti GB, et al. Impact of Routine Use of Surgical Drains on the Incidence of Complications with Robot-Assisted Radical Prostatectomy. J Endo. 2014. doi: 10.1089/end.2014.0268.
14. Silberstein JL, Sartor O. Long term survival of participants of the prostate cancer prevention trial. Asian J Androl. 2014; 16(3): 413-414.
15. Sartor O, Silberstein JL. Intensity-modulated radiation therapy for prostate cancer. NEJM. 2014; 370(7): 679.
16. Silberstein JL, Poon SA, Sjoberg D, et al. Long term oncologic outcomes of a Phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localized, high-risk prostate cancer. BJUI. 2015. doi: 10.1111/bju.12676
17. Silberstein JL, Bazzi WM, Vertosick E, et al. Clinical Outcomes for Local and Metastatic Testicular Sex Cord-Stromal Tumors. J Urology. 2014. doi: 10.1016/j.juro.2014.01.104
18. Silberstein JL, Pal SP, Lewis B, Sartor O. Current Clinical Challenges in Prostate Cancer. Translational Andrology and Urology. 2013.
19. Garg T, Bazzi WM, Silberstein JL, Abu-Rustum N, Leitao MM Jr, Laudone VP. Improving safety in robotic surgery: Intraoperative crisis checklist. J Surg Oncol. 2013; 108(3): 139-140. doi: 10.1002/jso.23363.
20. Power NE, Silberstein JL, Tarin T, et al. Endoscopic Spray cryotherapy for genitourinary malignancies: safety and efficacy in a porcine model. Ther Adv Urol. 2013; 5(3): 135-141. doi: 10.1177/1756287212465457
21. Silberstein JL, Eastham JA. Words of wisdom. Re: Radical prostatectomy versus observation for localized prostate cancer. EurUrol. 2013; 63(6): 1130-1131.
22. Power NE, Silberstein JL, Touijer K. Is Laparoscopic Partial Nephrectomy Already the Gold Standard for Small Renal Masses? Arch. Esp. Urol. 2013; 66(1): 90-98.
23. Silberstein JL, Eastham JA. LUTS, BPH and Prostate Cancer: Seek and Ye Shall Find. EUrol. 2013; 63(6): 1028-1029.
24. Poon SA, Silberstein JL, Chen LY, Ehdaie B, Russo P. Trends in Renal Surgery: An Analysis of Case Logs from Certifying Urologists. J Urol. 2013; 190(2): 464-469.
25. Silberstein JL, Poon SA, Maschino AS, et al. Urinary diversion practice patterns among certifying American urologists. J Urol. 2013; 189(3): 1042-1047. doi: 10.1016/j.juro.2012.08.240
26. Silberstein JL, Su D, Glickman L, et al. Case mix adjusted comparison of biochemical recurrence rates of open and robotic prostatectomy performed by experienced, high volume surgeons. BJUI. 2013; 111(2): 206-212. doi: 10.1111/j.1464-410X.2012.11638.x.
27. Silberstein JL, Sprenkle PC, Su D, et al. Neutrophil gelatinase-associated lipocalin (NGAL) levels in response to unilateral renal ischemia in a novel pilot two-kidney porcine model. BJUI. 2013; 112(4): 517-525. doi: 10.1111/bju.12066.
28. Kopp RP, Dicks BM, Goldstein I, et al. Does Radical Nephrectomy Increase the Risk of Erectile Dysfunction Compared to Partial Nephrectomy? A Cohort Analysis. BJU Int. 2013; 111(3Pt B).
29. Poon SA, Silberstein JL, Savage C, et al. Surgical practice patterns for male urinary incontinence among certifying American urologists. J Urol. 2012; 188(1): 205-210. doi: 10.1016/j.juro.2012.03.012
30. Power NE, Silberstein JL, Ghoneim TP, Guillonneau B, Touijer KA. Environmental impact of minimally invasive surgery in the United States; an estimate of CO2 footprint. J Endourol. 2012; 26(12): 1639-1644. doi: 10.1089/end.2012.0298
32. Silberstein JL, Adamy A, Maschino AC, et al. Systematic classification and prediction of postoperative complications following nephrectomy in patients with metastatic renal cell carcinoma. BJU Int. 2012; 110(9): 1276-1282. doi: 10.1111/j.1464-410X.2012.11103.x
33. Woldrich JM, Silberstein JL, Saltzstein SL, Derweesh IH, Downs TM. Penile Kaposis sarcoma in the state of California. Can J Urol. 2012; 19(2): 6178-6182.
34. Power NE, Maschino AC, Savage C, et al. Intraoperative mannitol use does not improve long-term renal function outcomes after minimally invasive partial nephrectomy. Urology. 2012; 79(4): 821-826. doi: 10.1016/j.urology.2011.11.064
35. Tarin TV, Power NE, Ehdaie B, et al. Prospective evaluation of outcome of lymph node positive bladder cancer treated with radical cystectomy and lymphadencetomy: effect of the level of node positivity. E Urol. 2012; 61(5): 1025-1030.
36. Matasar MJ, Shi W, Silberstein J, et al. Expert second-opinion pathology review of lymphoma in the era of the World health Organization classification. Ann Oncol. 2012; 23: 159.
37. Silberstein JL, Power NE, Vickers AJ, et al. Renal Function and Oncologic Outcomes of Parenchymal Sparing Ureteral Resection versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. J Urol. 2012; 187(2): 429-434. doi: 10.1016/j.juro.2011.09.150.
38. Silberstein JL, Vickers AJ, Power NE, et al. Pelvic Lymph Node Dissection for Patients with Elevated Risk of Lymph Node Invasion during Radical Prostatectomy: Comparison of Open, Laparoscopic and Robot-Assisted Procedures. J Endourol. 2011. doi: 10.1089/end.2011.0266
39. Power NE, Silberstein JL, Kulkarni GS, Laudone VP. The dorsal venous complex (DVC): dorsal venous or dorsal vasculature complex? Santorinis plexus revisited. BJU Int. 2011; 108: 930.
40. Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2: ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. Sci Transl Med. 2011; 3: 94ra72.
41. Bagrodia A, Mehrazin R, Bazzi WM, et al. Comparison of rates and risk factors for development of osteoporosis and fractures after radical or partial nephrectomy. Urology. 2011; 78: 614.
42. Silberstein JL, Power NE, Touijer KA. Laparoendoscopic single site (LESS) radical prostatectomy: a review of the initial experience. Minerva UrolNefrol. 2011; 63: 123.
43. Silberstein JL, Vickers AJ, Power NE, et al. Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy. Cancer. 2011; 117: 4855. doi: 10.1002/cncr.26132
44. Bazzi WM, Wagner O, Stroup SP, et al. Transrectal hybrid natural orifice transluminal endoscopic surgery (NOTES) nephrectomy in a porcine model. Urology. 2011; 77: 518. doi: 10.1016/j.urology.2010.10.057
45. Kopp RP, Parsons JK, Shiau J, et al. Prostate atypia: clinical and pathological variables associated with cancer diagnosis on repeat biopsy. Prostate Cancer Prostatic Dis. 2011; 14: 149. doi: 10.1038/pcan.2010.53
46. Silberstein JL, Parsons JK, Palazzi-Churas K, et al. Robot-assisted laparoscopic radical prostatectomy in men with immunodeficiency virus. Prostate Cancer Prostatic Dis. 2010; 13: 328. doi: 10.1038/pcan.2010.35
47. Silberstein JL, Parsons JK. Prostate cancer prevention: concepts and clinical recommendations. Prostate Cancer Prostatic Dis. 2010; 13: 300. doi: 10.1038/pcan.2010.18
48. Derweesh IH, Silberstein JL, Bazzi W, Kopp RP, Downs TM, Kane CJ. Laparo-endoscopic single-site surgery for radical and cytoreductive nephrectomy, renal vein thrombectomy, and partial nephrectomy: a prospective pilot evaluation. Diag Ther Endosc. 2010.
49. Kopp RP, Silberstein JL, Derweesh IH. Laparo-endoscopic Single-site Surgery (LESS) Nephrectomy with renal vein thrombectomy: initial report. BMC Urol. 2010; 10: 8.
50. Silberstein JL, Millard F, Mehrazin R, et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 2010; 106: 1270.
51. Silberstein JL, Parsons JK. Evidence-based principles of bladder cancer and diet. Urology. 2010; 75: 340. doi: 10.1016/j.urology.2009.07.1260.
52. Silberstein JL, Derweesh IH, Kane CJ. Lymph node dissection during robotic assisted radical prostatectomy: where do we stand? Prostate Cancer Prostatic Dis. 2009; 12: 227. doi: 10.1038/pcan.2009.17
53. Grabowski J, Silberstein J, Saltzstein SL, Saenz N. Renal tumors in the second decade of life: results from the California Cancer Registry. J Pediatr Surg. 2009; 44: 1148. doi: 10.1016/j.jpedsurg.2009.02.019
54. Silberstein J, Parsons JK. Hand assisted and total laparoscopic nephrectomy: a comparison. Journal of the Society of Laproendoscopic Surgeons. 2009; 13: 36.
55. Silberstein J, Parsons JK. Current concepts in diet and prostate cancer. Aging Health. 2008; 4: 495. doi: 10.2217/1745509X.4.5.495
56. Silberstein J, Grabowski J, Saltzstein SL, Kane CJ. Renal cell carcinoma in the pediatric population: results from the California Cancer Registry. Pediatric Blood & Cancer. 2009; 52: 237.
57. Silberstein J, Downs T, Lakin C, Kane CJ. HIV and prostate cancer: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2009; 12: 6.
58. Silberstein J, Lakin C, Parsons JK. Shock wave lithotripsy and renal hemorrhage. Rev Urol. 2008; 10: 236.
59. Silberstein J, Downs T, Goldstein I. Penile injection with silicone: case report and review of the literature. J Sex Med. 2008; 5: 2231.
60. Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E. Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology. 2008; 72: 318.
61. Silberstein J, Grabowski J, Lakin C, Goldstein I. Penile constriction devices: case report and review of the literature, and recommendations for extrication. J Sex Med. 2008; 5: 1747. doi: 10.1111/j.1743-6109.2008.00848.x
62. Silberstein J, Grabowski J, Parsons JK. Use of Vacuum-assisted Device for Fourniers Gangrene: A New Paradigm. Rev Urol. 2008; 10: 76.
63. Singh A, Kinoshita Y, Rovito PM Jr, et al. Higher than expected association of clinical prostate and bladder cancers. J Urol. 2005; 173: 1526. doi: 10.1097/01.ju.0000154700.80042.c6
64. Blaschke UK, Silberstein J, Muir TW. Protein engineering by expressed protein ligation. Methods Enzymol. 2000; 328: 478. 10.1016/S0076-6879(00)28414-0
1. Goldstein I, Silberstein JL. Physiology of Female Genital Sexual Arousal. In: Mulhall JP, Incrocci L, Goldstein I, Rosen R, eds. Current Clinical Urology, Cancer and Sexual Heath, 1st ed. New York: Humana Press, Chapter 5. 2011; 51-68.
2. Silberstein JL, Laudone VP. Pelvic Lymph Node Dissection. In: Eastham JA, Schaeffer, eds. Radical Prostatectomy: Surgical Perspectives, 1sted. New York: Springer Press, 2013.
3. Silberstein JL, Eastham JA. Counseling the patient with clinically localized, high-risk prostate cancer. In: Dicker AP, Trabulsi EJ, Kelly WK, eds. Current Multidisciplinary Oncology: Prostate Cancer. New York: Demos Press, 2013.
4. Silberstein JL. Simple Orchiectomy. In: Graham SD, Keane TE, eds. Glenns Urologic Surgery, 8th. New York: Lippincott Williams & Wilkins, 2014.